A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma

Assess patient-level utility of suggested pretreatment biomarkers of sunitinib in advanced renal cell carcinoma.

Kaplan-Meier analysis of data from a randomized, Phase II study (n = 292) suggested baseline predictive value for circulating soluble Ang-2 and MMP-2 and HIF-1α percentage of tumor expression.

Using this dataset, the sensitivity, specificity and area under the curve (AUC) were calculated, using receiver operating characteristic (ROC) curves.

Based on a ROC (sensitivity vs 1 - specificity) threshold AUC value of >0. 8, neither Ang-2 (0. 67) nor MMP-2 (0. 65), nor HIF-1α percentage of tumor expression (0. 65), performed appropriately from a patient-selection standpoint.

To properly assess potential biomarkers, sensitivity and specificity characteristics should be obtained by ROC analysis.

Future oncology (London, England). 2015 Dec 17 [Epub ahead of print]

Patricia A English, J Andrew Williams, Jean-François Martini, Robert J Motzer, Olga Valota, Richard E Buller

Pfizer Oncology, 10646 Science Center Drive, San Diego, CA 92121, USA. , Pfizer Oncology, 10646 Science Center Drive, San Diego, CA 92121, USA. , Pfizer Oncology, 10646 Science Center Drive, San Diego, CA 92121, USA. , Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. , Pfizer Oncology, via AM Mozzoni 12, Milan, 20152, Italy. , Pfizer Oncology, 10646 Science Center Drive, San Diego, CA 92121, USA.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe